Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. - Wikidata - awgldk - TriplyDB

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.

http://www.wikidata.org/entity/Q35204878

about

Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Tau passive immunization inhibits not only tau but also Aβ pathology Tau Immunotherapy.Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro.Tauopathies: Mechanisms and Therapeutic Strategies.Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice."Tau immunotherapy: Hopes and hindrances".Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice.Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein.A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities.

P2860

Q26748105-F7EF9DED-23E6-42A7-853E-F0C97A1FE571 Q33640390-01345C90-0527-46C6-BD30-3472F5C1F05B Q35972860-1827C024-6C57-4C03-A848-49F6F481E840 Q36484413-50CF5667-3061-4C60-8E85-89A76C5F5E7B Q37579019-54C1342D-A5B4-4C29-8CA0-593586FDC1E8 Q38628672-C23A08BD-997C-49CC-AA1C-A7098BD7812C Q41629521-FAB5ECCB-70FC-4F32-B121-E6E308BC0064 Q46383545-D33C491E-6C92-496C-BE5E-5D7D86E9EE81 Q47253592-F22D9F72-1E45-4BE5-A4F1-5227528B8289 Q47547728-7A926BC7-9F41-4AB5-92E0-E78C7567F251 Q47629452-2323E60A-978A-4756-8BAF-DA5CCD9C6CF5 Q50045202-55941520-F58D-4F3F-B78B-7EE5F8022C37 Q50525085-A7062A56-BB65-42F9-85F1-E0E7C118CCAD Q55118610-99143EDF-E67A-4142-9758-7211640D7CCB Q55238549-F4E80718-CD3F-483C-85A6-A3A5D1571764

P2860

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.

http://www.wikidata.org/entity/Q35204878

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.

@ast

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.

@en

type

label

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.

@ast

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.

@en

prefLabel

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.

@ast

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.

@en

P1433

Q35204878-4F8DC131-953C-4369-AA52-95D2C2BD2D7C

P1476

Q35204878-D718BC21-572F-4790-BC8B-5AF97FA1E504

P2093

Q35204878-0A0F507E-3CC3-4921-8477-F4D4101B9646

Q35204878-4A6EF016-2670-4687-8FC6-317BFBDF4A33

Q35204878-5A0E09A4-3240-4F98-95AD-760B46FD423E

Q35204878-618969AB-7FCF-49E1-9CB2-02160F92EFAB

Q35204878-76A749BA-028C-4A6D-ACA3-B1F998000EC9

Q35204878-B3E3C470-A3C8-4F72-801C-87529A66C9B2

Q35204878-E930E537-CF8D-4FE3-9EFF-33E75CC5E0EA

P2860

Q35204878-029BC715-EF89-4670-AF28-B5A36D0E7B89

Q35204878-05183D84-2E8E-4CD4-815C-D770F52F41E6

Q35204878-09FB59F9-3597-45A7-8A92-6C8049033DEB

Q35204878-1949E60C-4DF5-46A1-99F3-A24619837264

Q35204878-25D07E2D-0D5C-4F45-898A-D8254C564E0D

Q35204878-2DE0B5E4-D8FD-4E24-8185-A89FE07C1A83

Q35204878-35F196CF-868E-417E-AA3C-AB59B42F5ECC

Q35204878-36EE6B55-57A1-41F4-BB8B-72A723F24F5A

Q35204878-38C241BB-3E43-4098-AAED-14B307646012

Q35204878-38F44B3A-7FC5-439F-B1D7-45387A6DB2BC

P304

Q35204878-41ADCFFC-7E81-4405-AC1A-7F765AB7A2D9

P31

Q35204878-18FA5E63-6A26-4F35-B7E2-B9263330FDEC

P356

Q35204878-F4B6D983-97BD-4E3F-931E-810A13CB49A1

P433

Q35204878-2B452664-7336-4FE1-BD89-88A28984CD0F

P478

Q35204878-B5A31610-9DE3-4BB3-A9E1-67539F60404A

P577

Q35204878-DC10C45A-3AAF-45EF-8864-750EEC9A993D

P5875

Q35204878-9CD63196-6BCE-4133-83A6-CB1A60B91C62

P698

Q35204878-AB738C48-F741-4508-9DAD-208251467AFF

P921

Q35204878-F3D4EEC3-C26E-48DD-821F-49B23B9E67D3

P932

Q35204878-474F693D-F095-4454-92E9-11A029E7D9B2

P356

P1433

Annals of clinical and translational neurology

P1476

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.

@en

P2093

Hiroshi Eguchi

http://www.w3.org/2001/XMLSchema#string

Hiroshi Mori

http://www.w3.org/2001/XMLSchema#string

Taizo Taniguchi

http://www.w3.org/2001/XMLSchema#string

Takami Tomiyama

http://www.w3.org/2001/XMLSchema#string

Tomohiro Umeda

http://www.w3.org/2001/XMLSchema#string

Yoichi Matsumoto

http://www.w3.org/2001/XMLSchema#string

Yuichi Kunori

http://www.w3.org/2001/XMLSchema#string

P2860

Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model

Tau suppression in a neurodegenerative mouse model improves memory function

Neurodegenerative tauopathies

Prion-like transmission of protein aggregates in neurodegenerative diseases

Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.

Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice.

Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism.

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy

Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.

P304

241-255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACN3.171

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270649737

http://www.w3.org/2001/XMLSchema#string

P698

25815351

http://www.w3.org/2001/XMLSchema#string

P921

P932

4369274

http://www.w3.org/2001/XMLSchema#string